RHB-105 Effective for Eradication of Helicobacter pylori in Adults
THURSDAY, May 7, 2020 -- A novel rifabutin-based triple therapy (RHB-105) is effective for eradication of Helicobacter pylori, with eradication rates unaffected by resistance to clarithromycin or metronidazole, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 7, 2020 Category: Pharmaceuticals Source Type: news
Common antibiotics tied to miscarriages may also lead to birth defects
(Reuters Health) - Pregnant women have another reason to avoid taking a class of antibiotics that includes erythromycin, clarithromycin and azithromycin: it may increase their baby's risk of birth defects, a UK study suggests. (Source: Reuters: Health)
Source: Reuters: Health - March 6, 2020 Category: Consumer Health News Tags: healthNews Source Type: news
Common Antibiotics Linked To Increased Risk Of Birth Defects, Study Says
(CNN) — Taking some common antibiotics during the first trimester of pregnancy was linked with higher risk of birth defects, according to a new study.
The study, published Wednesday in the medical journal BMJ, found an increased risk of birth defects in the children of women who were prescribed macrolides during the first three months of pregnancy compared to mothers who were prescribed penicillin.
Macrolide antibiotics include erythromycin, clarithromycin and azithromycin, and they are used to treat infections, such as pneumonia, bronchitis and urinary, skin and sexually transmitted diseases. They are often prescrib...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 20, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Source Type: news
Macrolide Antibiotics Early in Pregnancy Tied to Birth Defects
Taking antibiotics like erythromycin, clarithromycin or azithromycin early in the course of pregnancy may increase the risk of birth defects. (Source: NYT Health)
Source: NYT Health - February 19, 2020 Category: Consumer Health News Authors: Nicholas Bakalar Tags: Antibiotics Pregnancy and Childbirth Birth Defects Heart Infections Source Type: news
FDA OKs First Rifabutin-Based H Pylori Therapy Talicia FDA OKs First Rifabutin-Based H Pylori Therapy Talicia
Talicia combines omeprazole, amoxicillin, and rifabutin and is designed to address growing bacterial resistance to standard clarithromycin-based H pylori therapy.FDA Approvals (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 4, 2019 Category: Intensive Care Tags: Infectious Diseases News Alert Source Type: news
Cancer-causing stomach bug has become TWICE as hard to treat with antibiotics in the last 20 years
Rates of resistance of Helicobacter pylori against clarithromycin jumped from under 10 per cent in 1998 to almost 22 per cent last year, according to French scientists. (Source: the Mail online | Health)
Source: the Mail online | Health - October 21, 2019 Category: Consumer Health News Source Type: news
Featured Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
The review 'Adverse events in people taking macrolide antibiotics' asked, “Will people taking a macrolide antibiotic experience more adverse events than those treated with placebo?”Macrolide antibiotics are one of many types of antibiotic. They are commonly used to treat both acute and chronic infections. The four most commonly used macrolides are azithromycin, clarithromycin, erythromycin, and roxithromycin. People taking macrolide antibiotics are at risk of experiencing adverse events such as nausea, diarrhoea or rashes.Lead author of the review Malene Plejdrup Hansen explains, “This review was undertaken to qua...
Source: Cochrane News and Events - December 17, 2018 Category: Information Technology Authors: Katie Abbotts Source Type: news
Lannett Announces Expanded Agreement With Strategic Alliance Partner, HEC Pharm Group, To Distribute Two FDA-Approved Products
Company Has Commenced Launch of Clarithromycin and Expects to Begin Marketing Entacapone In Early Calendar Year 2019
PHILADELPHIA, Nov. 6, 2018 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (NYSE: LCI) today announced that it has e... Biopharmaceuticals, Licensing, Distribution Lannett Company, Sunshine Lake, HEC Pharm Group, clarithromycin, entacapone (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 6, 2018 Category: Pharmaceuticals Source Type: news
March 2, 2018 This Week in Cardiology March 2, 2018 This Week in Cardiology
Vegetarian vs Mediterranean diets, a clarithromycin alert, a new stent, best choice of IV fluid, and early work in prevention Type I diabetes are discussed in this week ' s podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 2, 2018 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
FDA: Clarithromycin Risky for Patients With Heart Disease
The FDA is warning clinicians about prescribing clarithromycin to patients with heart disease because of the risk for serious cardiac and other complications -- and even death -- that persists years later. (Source: AAFP News)
Source: AAFP News - March 1, 2018 Category: Primary Care Source Type: news
FDA Warns Heart Patients About Antibiotic Clarithromycin
Title: FDA Warns Heart Patients About Antibiotic ClarithromycinCategory: Health NewsCreated: 2/23/2018 12:00:00 AMLast Editorial Review: 2/26/2018 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - February 26, 2018 Category: Cardiology Source Type: news
D.C. Week: White House Takes New Poke at ACA
(MedPage Today) -- FDA warns patients of new risks of clarithromycin (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - February 24, 2018 Category: Infectious Diseases Source Type: news
Antibiotic linked to higher death rates heart disease
The FDA has issued a warning that the broad-spectrum antibiotic clarithromycin may raise the risk of death for heart disease patients and is advising sufferers to steer clear of the drug. (Source: the Mail online | Health)
Source: the Mail online | Health - February 23, 2018 Category: Consumer Health News Source Type: news
FDA Warns Heart Patients About Antibiotic Clarithromycin
FRIDAY, Feb. 23, 2018 -- The antibiotic clarithromycin (brand name: Biaxin) may increase the long-term risk of heart problems and death in patients with heart disease, according to U.S. health officials.
As a result, the federal Food and Drug... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 23, 2018 Category: General Medicine Source Type: news
FDA Alert: Clarithromycin Risky in Patients With Heart Disease FDA Alert: Clarithromycin Risky in Patients With Heart Disease
The agency adds a new warning about the increased risk for death in patients with heart disease prescribed the antibiotic clarithromycin and recommends considering an alternative when possible.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news
